Goldman Sachs
NPCE icon

Goldman Sachs’s Neuropace NPCE Stock Holding History

Goldman Sachs’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.38M Sell
149,566
-25,796
-15% -$415K ﹤0.01% 4541
2026
Q1 		$2.31M Buy
175,362
+10,652
+6% +$160K ﹤0.01% 4413
2025
Q4 		$2.54M Sell
164,710
-21,828
-12% -$292K ﹤0.01% 4360
2025
Q3 		$1.92M Buy
186,538
+127,885
+218% +$1.21M ﹤0.01% 4519
2025
Q2 		$653K Buy
58,653
+24,427
+71% +$305K ﹤0.01% 4996
2025
Q1 		$421K Sell
34,226
-8,057
-19% -$101K ﹤0.01% 5287
2024
Q4 		$473K Buy
42,283
+19,857
+89% +$173K ﹤0.01% 5278
2024
Q3 		$156K Sell
22,426
-1,522
-6% -$11.1K ﹤0.01% 5511
2024
Q2 		$181K Sell
23,948
-115,895
-83% -$1.17M ﹤0.01% 5293
2024
Q1 		$1.85M Buy
+139,843
New +$1.99M ﹤0.01% 3926

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Goldman Sachs's NPCE Position: Q2 2026 in Review

Goldman Sachs reduced its Neuropace (NPCE) stake by 15% in Q2 2026, selling an estimated $415K and leaving 149,566 shares worth $2.38M. The position accounts for ﹤0.01% of the portfolio, ranked #4541.

Goldman Sachs first reported a position in NPCE in Q1 2024 and has held it in 10 quarters since. The position peaked at $2.54M in Q4 2025. 113 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

  • Goldman Sachs held 149,566 shares of Neuropace worth $2.38M as of Q2 2026.
  • Goldman Sachs sold 25,796 Neuropace shares in Q2 2026, an estimated $415K.
  • Neuropace made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #4541 holding.
  • Goldman Sachs first reported a position in Neuropace in Q1 2024 and has held it in 10 quarters since.
  • Goldman Sachs's Neuropace position peaked at $2.54M in Q4 2025.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.